Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04269356 · ClinicalTrials.gov registry record · Phase 1
Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04269356 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 8 participants.
The verdict
NCT04269356, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.
Interventions
- DRUG BMS-986256
- DRUG Milk of magnesia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-02-18 |
| Est. Completion | 2021-03-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04269356
The ClinicalTrials.gov registry entry for NCT04269356 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which BMS-986256 is the first listed.
NCT04269356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04269356 about?
NCT04269356 is a clinical study titled "Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants". The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.
What is the current status of trial NCT04269356?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-02-18. Estimated completion is 2021-03-30.
What interventions are being tested in trial NCT04269356?
The interventions under investigation include: BMS-986256 (DRUG), Milk of magnesia (DRUG).
Who is sponsoring clinical trial NCT04269356?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.